Wellness

Tiered incentives may encourage more workers to get active, but for employers they represent an increase in administrative overhead, says David Contorno, CEO of Lake Norman Benefits.

Acknowledging the explosive growth of robo-advisers, FINRA this week released guidance on digital investment advice for companies considering using such means.

How the concept of paying employees to encourage certain behaviors is making its way into other areas of benefits that advisers need to know about.

Hospital market power, not technologies or regulation, is behind escalating prices, says benefits expert Joseph Jenkins, M.D.

While plan sponsors and others debate whether wellness programs actually save healthcare costs, a more pressing concern for employers is the real price of poor workplace health.

Alicia H. Munnell, director of the Center for Retirement Research at Boston College, shares her thoughts about why Congress should pass a law mandating auto-enrollment and auto-escalation in 401(k) plans.

Steve Miller, the pharmacy benefit manager’s chief medical officer, addresses the key cost drivers and what the PBM is doing to guard against increases.

Hospital market power, not regulation or new medical technologies is behind escalating prices, says benefits expert Joseph Jenkins, M.D.

The investment firm announces plans to acquire Honest Dollar, an Austin, Texas-based benefits vendor that targets small and mid-sized businesses.

Generic drugs are usually significantly cheaper for plan sponsors than brand-name drugs. Here’s a look at 10 drugs coming off patent in 2016. And although the FDA hasn’t yet approved generics for many of the following blockbuster drugs that are coming off patent this year, in most cases there are generics in the pipeline, according to Dickson Data Blog.